Company Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:11 17/07/2025 pm IST			5-day change	1st Jan Change
34.25 ^GBX	+5.38%		+8.73%	-31.50%

17/07	Avacta Group Raises GBP3 Million via Share Placement Offer	MT
17/07	Avacta announces equity fundraise of £3.25 mln	RE

Business description: Avacta Group Plc

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Number of employees: 151

Sales by Activity: Avacta Group Plc

Fiscal Period: December	2020	2021	2022	2023	2024
Therapeutics	16.25L	21.62L	54.81L	20.55L	1L
Diagnostics	5L	8L	41.72L	2.12Cr	-
Animal Health	14.92L	-	-	-	-

See all business segments

Geographical breakdown of sales: Avacta Group Plc

Fiscal Period: December	2020	2021	2022	2023	2024
South Korea	-	14L	54.81L	20.55L	1L
Rest of World	-	-	-	6L	-
France	-	-	12.96L	41.2L	-
Rest of Asia	-	74T	7T	-	-
Rest of Europe	7L	1L	2L	36.88L	-
North America	4L	8L	2L	21T	-
Asia	14.73L	-	-	-	-
United Kingdom	10.76L	5L	25.32L	1.28Cr	-

See all geographic segments

Executive Committee: Avacta Group Plc

Manager	Title	Age	Since
Christina Coughlin CEO	Chief Executive Officer	55	01/05/2024
Brian Hahn DFI	Director of Finance/CFO	50	13/01/2025
David Liebowitz CTO	Chief Tech/Sci/R&D Officer	-	01/07/2025
Simon Bennett PRN	Corporate Officer/Principal	-	19/12/2023

See AVACTA GROUP PLC governance

Composition of the Board of Directors: Avacta Group Plc

Director	Title	Age	Since
Paul Fry BRD	Director/Board Member	59	03/02/2020
Mark Goldberg BRD	Director/Board Member	70	18/08/2021
Christina Coughlin BRD	Director/Board Member	55	21/03/2022
Shaun Chilton CHM	Chairman	58	20/06/2024
Darlene Deptula-Hicks BRD	Director/Board Member	67	26/06/2024
David Bryant BRD	Director/Board Member	58	28/05/2025
Richard Hughes BRD	Director/Board Member	57	28/05/2025

Composition of the Board of Directors

Shareholders: Avacta Group Plc

Name	Equities	%	Valuation
Hargreaves Lansdown Asset Management Ltd. 8.305 %	3,12,44,000	8.305 %	13 M p
Conifer Management LLC 3.151 %	1,18,54,734	3.151 %	5 M p
Baillie Gifford & Co. 2.691 %	1,01,24,371	2.691 %	4 M p
IG Markets Ltd. 2.551 %	95,99,000	2.551 %	4 M p
Jarvis Investment Management Ltd. 2.513 %	94,55,000	2.513 %	4 M p

List of AVACTA GROUP PLC shareholders

Company details: Avacta Group Plc

Avacta Group Plc

Thorp Arch Estate Ash Way, Wetherby

LS23 7FA, Leeds

+44 203 9110353

http://www.avacta.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AVACTA GROUP PLC	+5.38%	+8.73%	-47.31%	-68.86%	18Cr
ARGENX SE	+0.99%	+1.11%	+15.92%	+35.58%	3.48TCr
WUXI APPTEC CO., LTD.	+2.80%	+15.51%	+106.58%	-22.84%	3.23TCr
BIONTECH SE	-1.29%	-2.53%	+28.41%	-31.22%	2.73TCr
SUMMIT THERAPEUTICS INC.	-2.26%	+6.76%	+196.78%	+2,411.82%	2.05TCr
INSMED INCORPORATED	-0.40%	+7.77%	+37.90%	+350.37%	1.98TCr
AKESO, INC.	-0.72%	+22.35%	+244.10%	+506.13%	1.6TCr
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	+6.19%	+151.78%	-62.93%	1.47TCr
GENMAB A/S	+1.00%	+1.86%	-22.33%	-44.05%	1.36TCr
EXELIXIS, INC.	+0.13%	-0.66%	+99.33%	+110.26%	1.22TCr
Average	+0.56%	+6.70%	+81.12%	+318.42%	1.91TCr
Weighted average by Cap.	+0.21%	+5.49%	+86.67%	+334.31%